Literature DB >> 10677746

Risk of death due to chronic chagasic cardiopathy.

E C Manzullo1, R Chuit.   

Abstract

In this longitudinal study 5,710 people were included. The inclusion criteria were two positive serological results for Trypanosoma cruzi infection, 15 and 50 years old and no other demonstrable disease at the time of study. In the five year follow up 1,117 patients were lost. The follow up involved yearly evaluation of serology, clinical examination, X-ray of thorax, and ECG, for 4,593 patients and 263 were contacted at home because they did not assist for their clinical consultant. Time average of follow up was 5.3 years. Eighty nine (1.5%) of the 4,593 patients died during the follow-up period, 63 (71%) by cardiac insufficiency (CI) and 26 (29%) by severe ventricular arrhythmias. Diagnosis of cardiomegaly was present in all the patients with diagnosis of CI and in 15 (5%) of the patients with diagnosis of arrhythmias. The ECG alterations of these patients show 61 right bundle branch block (RBBB), associated or not with left anterior hemiblock (LAHB), 47 pathological Q wave and 70 primary repolarization alterations; 61 had polyfocal ventricular arrhythmia. The death rate was similar in the sexes and was more frequent between 40 and 50 years of age. Information on 1,380 recuperated patients shows that 15 died with no previous symptoms and without medical assistance and were interpreted as sudden death. The latest ECG in three follow-up of these patients indicates (before death) that only one had normal study and 14 presented 12 RBBB; 9 LAHB; 7 isolated ventricular arrhythmia; 10 repolarize alterations; 2 pathological Q wave, 10 patients of them with RBBB and repolarize alterations. In all the cases we had people between 35 and 43 years old, 9 men and 6 women. This study shows that in Chagas disease is possible to differentiate two risk groups. A low risk death group that have normal ECG and clinical evaluation during the follow up, and a high risk group associate ECG with RBBB and primary alterations of repolarization and/or inactivation zones with not annual clinical evaluation.

Entities:  

Mesh:

Year:  1999        PMID: 10677746     DOI: 10.1590/S0074-02761999000700060

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  12 in total

1.  Cloning and expression analysis of two novel paraflagellar rod domain genes found in Trypanosoma cruzi.

Authors:  April K Clark; Gennadiy Kovtunovych; Sachin Kandlikar; Shailesh Lal; Gabrielle A Stryker
Journal:  Parasitol Res       Date:  2005-05-26       Impact factor: 2.289

2.  Efficacy and Safety of Granulocyte-Colony Stimulating Factor Therapy in Chagas Cardiomyopathy: A Phase II Double-Blind, Randomized, Placebo-Controlled Clinical Trial.

Authors:  Carolina T Macedo; Ticiana F Larocca; Márcia Noya-Rabelo; Roque Aras; Cristiano R B Macedo; Moisés I Moreira; Alessandra C Caldas; Jorge A Torreão; Victor M A Monsão; Clarissa L M Souza; Juliana F Vasconcelos; Milena R Bezerra; Daniela P Petri; Bruno S F Souza; Antônio G F Pacheco; André Daher; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Front Cardiovasc Med       Date:  2022-06-09

Review 3.  Management of Cardiovascular Disease in Patients With COVID-19 and Chronic Chagas Disease: Implications to Prevent a Scourge Still Larger.

Authors:  Reinaldo Bulgarelli Bestetti; Edimar Alcides Bocchi; Renato Bestetti; Victor Sarli Issa; Rosemary Aparecida Furlan-Daniel; Marcelo Arruda Nakazone
Journal:  Front Med (Lausanne)       Date:  2022-06-29

4.  Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure.

Authors:  R J Viotti; C Vigliano; S Laucella; B Lococo; M Petti; G Bertocchi; B Ruiz Vera; H Armenti
Journal:  Heart       Date:  2004-06       Impact factor: 5.994

5.  Rare Pathogenic Variants in Mitochondrial and Inflammation-Associated Genes May Lead to Inflammatory Cardiomyopathy in Chagas Disease.

Authors:  Edecio Cunha-Neto; Christophe Chevillard; Maryem Ouarhache; Sandrine Marquet; Amanda Farage Frade; Ariela Mota Ferreira; Barbara Ianni; Rafael Ribeiro Almeida; Joao Paulo Silva Nunes; Ludmila Rodrigues Pinto Ferreira; Vagner Oliveira-Carvalho Rigaud; Darlan Cândido; Charles Mady; Ricardo Costa Fernandes Zaniratto; Paula Buck; Magali Torres; Frederic Gallardo; Pauline Andrieux; Sergio Bydlowsky; Debora Levy; Laurent Abel; Clareci Silva Cardoso; Omar Ribeiro Santos-Junior; Lea Campos Oliveira; Claudia Di Lorenzo Oliveira; Maria Do Carmo Nunes; Aurelie Cobat; Jorge Kalil; Antonio Luiz Ribeiro; Ester Cerdeira Sabino
Journal:  J Clin Immunol       Date:  2021-03-03       Impact factor: 8.542

6.  Benzonidazole therapy modulates interferon-γ and M2 muscarinic receptor autoantibody responses in Trypanosoma cruzi-infected children.

Authors:  Romina A Cutrullis; Guillermo F Moscatelli; Samanta Moroni; Bibiana J Volta; Rita L Cardoni; Jaime M Altcheh; Ricardo S Corral; Héctor L Freilij; Patricia B Petray
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

7.  Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease.

Authors:  Fabiane L de Oliveira; Tania C Araújo-Jorge; Elen M de Souza; Gabriel M de Oliveira; Wim M Degrave; Jean-Jacques Feige; Sabine Bailly; Mariana C Waghabi
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

Review 8.  Sudden Cardiac Death Risk Stratification and Prevention in Chagas Disease: A Non-systematic Review of the Literature.

Authors:  Roberto Keegan; Cynthia Yeung; Adrian Baranchuk
Journal:  Arrhythm Electrophysiol Rev       Date:  2020-12

9.  Utility of a novel risk score for prediction of ventricular tachycardia and cardiac death in chronic Chagas disease - the SEARCH-RIO study.

Authors:  P R Benchimol-Barbosa; B R Tura; E C Barbosa; B K Kantharia
Journal:  Braz J Med Biol Res       Date:  2013-10-22       Impact factor: 2.590

10.  Inflammation Enhances the Risks of Stroke and Death in Chronic Chagas Disease Patients.

Authors:  Paulo Marcos Matta Guedes; Cléber Mesquita de Andrade; Daniela Ferreira Nunes; Nathalie de Sena Pereira; Tamyres Bernadete Dantas Queiroga; George Luiz Lins Machado-Coelho; Manuela Sales Lima Nascimento; Maria Adelaide Do-Valle-Matta; Antônia Cláudia Jácome da Câmara; Egler Chiari; Lúcia Maria da Cunha Galvão
Journal:  PLoS Negl Trop Dis       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.